@article{Wilkinson_T-2023_151607,
title = {A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: Accord-2},
author = {Wilkinson, T. and De Soyza, A. and Carroll, M. and Chalmers, J. and Crooks, M. and Griffiths, G. and Shankar-Hari, M. and Ho, L. and Horsley, A. and Kell, C. and Lara, B. and Mishra, B. and Moate, R. and Page, C. and Pandya, H. and Raw, J. and Reid, F. and Saralaya, D. and Scott, I. and Siddiqui, S. and Ustianowski, A. and van Zuydam, N. and Woodcock, A. and Singh, D.},
month = {aug},
year = {2023},
abstract = {BACKGROUND: Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving outcomes in ACCORD-2 (EudraCT: 2020-001736-95).},
journal = {ERJ Open Research},
publisher = {European Respiratory Society},
url = {https://doi.org/10.1183/23120541.00249-2023},
}
